HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goetz, C. G. Articles by Shannon, K. M. Search for Related Content PubMed PubMed Citation Articles by Goetz, C. G. Articles by Shannon, K. M.

Progression of Parkinson's disease without levodopa

Department of Neurological Sciences, Rush University/Rush-Pres-byterian St. Luke's Medical Center, Chicago, IL.

We studied 100 consecutive patients with Parkinson's disease (PD) who were not receiving levodopa and followed them until symptoms advanced and levodopa was given. Eighty-three patients eventually received levodopa; 50% started within 36 months after a mean duration of symptoms of 48 months. Patients starting on levodopa showed significant progression of their disease compared with their baseline examination. These data have direct applicability to the design and implementation of future protocols aimed at preventing disease progression of PD.

Address correspondence and reprint requests to Dr. Goetz, Department of Neurological Sciences, Rush University/Rush-Presbyterian St. Luke's Medical Center, 1753 West Congress Parkway, Chicago, IL 60612.

Supported by grants from the United Parkinson Foundation and the Boothroyd Foundation, Chicago, IL.

Received April 28, 1986. Accepted for publication in final form August 6, 1986.

This article has been cited by other articles:

				W. Poewe The need for neuroprotective therapies in Parkinson's disease: A clinical perspective Neurology, May 23, 2006; 66(10_suppl_4): S2 - S9. [Abstract] [Full Text]

				B. C. Tilley, Y. Y. Palesch, K. Kieburtz, B. Ravina, P. Huang, J. J. Elm, K. Shannon, G. F. Wooten, C. M. Tanner, G. C. Goetz, et al. Optimizing the ongoing search for new treatments for Parkinson disease: Using futility designs Neurology, March 14, 2006; 66(5): 628 - 633. [Abstract] [Full Text] [PDF]

				J. Jankovic and A. S. Kapadia Functional Decline in Parkinson Disease Arch Neurol, October 1, 2001; 58(10): 1611 - 1615. [Abstract] [Full Text] [PDF]

				W. C. Koller, J. T. Hutton, E. Tolosa, and R. Capilldeo Immediate-release and controlled-release carbidopa/levodopa in PD : A 5-year randomized multicenter study Neurology, September 1, 1999; 53(5): 1012 - 1012. [Abstract] [Full Text] [PDF]

				E. D. Louis, M. X. Tang, L. Cote, B. Alfaro, H. Mejia, and K. Marder Progression of Parkinsonian Signs in Parkinson Disease Arch Neurol, March 1, 1999; 56(3): 334 - 337. [Abstract] [Full Text] [PDF]

				M. P. McDermott, J. Jankovic, J. Carter, S. Fahn, S. Gauthier, C. G. Goetz, L. I. Golbe, W. Koller, A. E. Lang, C. W. Olanow, et al. Factors Predictive of the Need for Levodopa Therapy in Early, Untreated Parkinson's Disease Arch Neurol, June 1, 1995; 52(6): 565 - 570. [Abstract] [PDF]

				DATATOP: A Multicenter Controlled Clinical Trial in Early Parkinson's Disease: Parkinson Study Group Arch Neurol, October 1, 1989; 46(10): 1052 - 1060. [Abstract] [PDF]

				C. H. Markham and S. G. Diamond Modification of Parkinson's Disease by Long-term Levodopa Treatment-Reply Arch Neurol, January 1, 1988; 45(1): 14 - 14. [Abstract] [PDF]